GlassScriptPhysician profile
Heather M Gilmer
NPI 1477706323
$1,957.74
in general payments reported to CMS, 2019-2025
19 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $315 · 2023: $349 · 2024: $512 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $551.87 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $422.51 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $337.00 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $139.32 | 2021-2025 | |
| Amgen INC. | $116.58 | 2022-2024 | Repatha, Otezla |
| Abbvie INC. | $67.90 | 2022-2024 | |
| Astellas Pharma US INC | $55.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $53.54 | 2021-2023 | Eliquis |
| Merck Sharp & Dohme LLC | $32.21 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $24.75 | 2024 | Austedo Xr |
| Averitas Pharma INC. | $22.47 | 2025 | Qutenza |
| Abbott Laboratories | $21.91 | 2023 | Proclaim |
| Seqirus USA INC | $19.29 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.39 | 2023 | Rexulti |
| Exact Sciences Corporation | $15.90 | 2025 | The Cologuard Plus Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $15.89 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.75 | 2024 | Nuzyra |
| Glaxosmithkline, LLC. | $14.30 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gilmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.